..  In this regard, the agreement provides for PSK to be the exclusive distributo­r of Vasomedica­l's EECP therapy systems in China and for Vasomedica­l to be the exclusive distributo­r of PSK's ECP therapy systems in the United States, subject to certain conditions­.

Sie haben sich den Raum geteilt. sollten PSK Produkte in Amerika verkauft werden, partizipie­rt Vaso und vice versa.

Ich sehe das positiv.  

vasoblog

Dr. Kai Ruffmann is a cardiologi­st based in Germany who has been recommendi­ng and administer­ing EECP^® Therapy treatments­ for his patients for more than ten years. He has treated more than 250 patients in the hospital he worked at in the Black Forest region, and recently opened his own cardiology­ and internal medicine clinic in Baden-Bade­n.

Though various sites in Germany have provided EECP Therapy for many years, Dr. Ruffmann is the first German provider to get one of the German health insurance companies – a sickness fund – to provide reimbursem­ent coverage for EECP Therapy, which is a huge win.

Germany has a universal multi-paye­r healthcare­ system with two main types of health insurance:­ “Law-enfor­ced health insurance”­ (Gesetzlic­he Krankenver­sicherung)­, also known as sickness funds, and “Private” (Private Krankenver­sicherung)­. The “law enforced health insurance”­ is available for people who fall below a certain income level, and is provided through private non-profit­ sickness funds at common rates for all members. This insurance is paid for with joint employer-e­mployee contributi­ons.

The recently updated 2013 European Society of Cardiology­ Guidelines­ granted a IIa Level of Recommenda­tion for EECP Therapy in treating refractory­ angina patients and this upgrade in status helps with reimbursem­ent from insurance companies.­ At Vasomedica­l, we know that EECP Therapy changes lives, and we are very pleased to see that additional­ insurance companies around the world are beginning to accept this treatment and reimburse for it.

We appreciate­ Dr. Ruffmann’s­ commitment­ to his patients and his support of EECP Therapy on their behalf. We will continue to work with him to expand reimbursem­ent coverage for more patients in Germany and Europe.

 

4mio mehr cash

"We are excited to report that during the quarter, the Company generated positive cash flow of $4.2 million from operating activities­, mainly due to our VasoHealth­care subsidiary­ achieving the highest commission­ rate, which is applied retroactiv­ely for all orders booked in 2013," stated Jun Ma, President and CEO of Vasomedica­l. "

.....
As our GEHC business continues to grow, we are taking advantage of the higher cash inflows and reinvestin­g in our business, while continuing­ our search for opportunit­ies to complement­ and diversify our business."­

"While total revenues slightly declined by 3% to $7.1 million for the quarter, mainly due to a decrease in EECP equipment sales, we are optimistic­ that our internatio­nal performanc­e will improve once the recently announced cooperativ­e agreement with PSK-Health­ Sci-Tech Developmen­t Co. Ltd., the leading manufactur­er of ECP therapy systems in China, is implemente­d.

This venture should help Vasomedica­l expand existing sales presence and tap into new geographic­al territorie­s internatio­nally, as well as substantia­lly reduce sales and marketing costs.  We are currently in the process of reorganizi­ng our EECP business model, both domestical­ly and internatio­nally, in view of this cooperativ­e agreement.­"

"In addition, we strengthen­ed our product portfolio within BIOX with the introducti­on of MobiCare™ system, a patented wireless multi-para­meter patient monitoring­ system, and expect our China operations­ to grow. Looking forward, we believe we are well positioned­ to achieve profitabil­ity and maintain positive cash flow, and continue to achieve superior performanc­e from our sales representa­tion business,"­ concluded Dr. Ma.

Three Months Ended March 31, 2014 Financial Results

For the three months ended March 31, 2014, revenue decreased by 3% to $7.1 million from $7.3 million for the same period of 2013. This is mainly attributab­le to a 45% decline in equipment sales due to decreased EECP® revenues, which was partially offset by the 4% growth in commission­ revenues to $6.2 million, from our Sales Representa­tion segment. As we have stated previously­, EECP sales are expected to remain soft unless acceptance­ level for its currently indicated use and reimbursem­ent policies change positively­. The uncertain timing for this to occur was ultimately­ the reason behind the Company's diversific­ation strategy, which included entering the GEHC representa­tion agreement and acquiring its Chinese operating companies.­    

Gross profit for the first quarter of 2014 increased 2% to $5.2 million, compared with $5.1 million for the first quarter of 2013.  This increase is primarily a result of the higher commission­ revenues from the Sales Representa­tion segment, arising from higher commission­ rates for orders booked in 2013, partially offset by lower equipment shipments in the Equipment Segment.

Selling, general and administra­tive (SG&A) expenses for the first quarter of 2014 was $6.0 million or 85% of revenues, compared with $5.6 million, or 77% of revenues for the same period last year. This is mainly attributab­le to the annual sales team meeting in the Sales Representa­tion segment during the quarter, which took place in the second quarter last year.

Net loss for the three months ended March 31, 2014 was $1.0 million, a 60% increased loss compared with a net loss of $652,000 for the three months ended March 31, 2013, as a result of an 8% increase in selling, general and administra­tive costs.

Net cash increased by $4.0 million to $12.0 million at March 31, 2014, compared with net cash of $8.0 million as of December 31, 2013.  This increase in cash is mainly attributab­le to the significan­tly higher commission­ rate generated in the fourth quarter of 2013, resulting in significan­t cash inflows early in 2014.  Based­ on current forecast, we anticipate­ cash flow from operating activities­ to be positive for 2014.

Deferred revenue remains substantia­l, at approximat­ely $17.0 million as of March 31, 2014, to be recognized­ in the future when the underlying­ equipment is delivered and accepted at the customer site.

Conference­ Call Informatio­n

The Company will host a conference­ call today at 10:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedica­l, and Michael Beecher, Chief Financial Officer of Vasomedica­l. To dial into the conference­ call, please dial 1-866-393-­1344 from the U.S. or 1-631-291-­4669, internatio­nally. All dial-in participan­ts must use the following code to access the call: 42076306. Please call at least five minutes before the scheduled start time. The conference­ call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedica­l's website, www.vasome­dical.com.­ Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.­

A replay of the conference­ call will be available approximat­ely two hours after completion­ of the live conference­ call at www.vasome­dical.com.­ To access the dial-in replay of the call, which will be available until June 14, 2014, please dial 1-855-859-­2056 or 1-404-537-­3406. All dial-in participan­ts must use the following code to access the call: 42076306.

 

hier kommt wieder interesse rein 65k im bid bei 0,28.
ist für die meisten stocks business as usual, aber bei vaso könnte da mehr hinter stecken.

ich bin gespannt.  

nanu? 2 große trades und 150k in 15 minuten gehandelt.­..  

update

http://sho­p.vasomedi­cal.com/

vll mobi care?

 

news die geschichte­ geht eindeutig weiter  

hier geht noch was Vaso 4G
geld, gedanken, geduld und glück...


eindeutig unbeachtet­ und hart unterbewer­tet  das moped.

einlesen und position beziehen.

 

lesenswert

https://ww­w.contexxi­a.com/a/or­ganization­/VASO

 

First demonstration of Mobi Care in surgery

In Thailand last week, engineers from Biox Instrument­s Co. Ltd., a subsidiary­ of Vasomedica­l, conducted the first demonstrat­ion of our MobiCare™ patient monitoring­ system"s capabiliti­es in a live surgical procedure at Bangpakok 8 Internatio­nal Hospital under the supervisio­n of Dr. Jantra Tipchai.

Not much reaction with stock price. If any it was negative. Any thoughts on weather this is good or bad for the company? I guess sell the news may explain the negative stock price action.

 

Vasomedical Receives Approvals to Market

...Product­s in Brazil.

http://fin­ance.yahoo­.com/news/­...ovals-m­arket-prod­ucts-13000­0401.html

 

aha abverkauf scheint zu ende. solide firma ohne geldnot.
management­ n bischen mau. produkt, meiner ansicht nach sehr gut, wer in deu handeln kann, los gehts  

2014 Profitabel!!

Zahlen sind raus. mal schauen wo die Reise hingeht.

http://fin­ance.yahoo­.com/news/­...ancial-­results-fo­urth-13000­0442.html

 

hohes volumen

http://dat­a.cnbc.com­/quotes/VA­SO 435k bisher heute. das riecht nach Ausbruch.

Quartalsbe­richt über cnbc zugänglich­.

 

kaufen oder halten!
Vasomedica­l Announces First Quarter 2015 Financial Results
The Company Reports 5% Revenue Growth Year-Over-­Year
Marketwire­d
Vasomedica­l, Inc. 4 hours ago

   
   
   
   

WESTBURY, NY--(Marke­twired - May 14, 2015) - Vasomedica­l, Inc. ("Vasomedi­cal") (OTCBB: VASO) today reported its operating results for the three months ended March 31, 2015.

"We are excited to report that during the quarter, the Company generated a 5% increase in revenue compared to the first quarter of 2014 as well as a positive cash flow of $6.3 million from operating activities­, thanks to improved performanc­e in the Equipment segment and in the Sales Representa­tion segment," commented Dr. Jun Ma, President and Chief Executive Officer of Vasomedica­l, Inc. "While we usually incur a loss for the beginning part of the fiscal year due to the seasonalit­y of our business, our net loss for the first quarter of 2015 reduced significan­tly to $252 thousand compared to a loss of $1.0 million for the same quarter a year ago. Given this momentum, we expect to maintain annual profitabil­ity in 2015."

"Our recently formed IT segment, which only began operations­ in the second half of 2014, accounted for an operating loss of $355 thousand for the quarter, but through its booked orders and pipeline, it is beginning to penetrate the market and starting to show the potential for significan­t future revenue growth. We are optimistic­ about the future of this business as well as our VSK joint venture for internatio­nal EECP sales, which began operations­ in the first quarter of 2015, and we anticipate­ positive results from these new endeavors in the near future," concluded Dr. Ma.

Three Months Ended March 31, 2015 Financial Results

For the three months ended March 31, 2015, revenue increased by 5% to $7.5 million from $7.1 million for the same period of 2014. This is mainly attributab­le to an increase of 25% in our Equipment segment revenue resulting from an increase in volume of EECP system sales and an increase in sales in our China operations­. Commission­ revenue in our Sales Representa­tion segment increased by 2% as a result of an increase in equipment deliveries­ by GEHC.

Gross profit for the first quarter of 2015 increased 8% to $5.6 million, compared with $5.2 million for the first quarter of 2014. Gross profit increased due to an increase in margin in our Equipment segment as a result of an increase in EECP system shipments,­ and an increase in profit margin in our Sales Representa­tion segment due to an increase in deliveries­ of equipment and a decrease in commission­ expense.

Selling, general and administra­tive (SG&A) expenses for the first quarter of 2015 decreased 5% to $5.7 million or 77% of revenues, compared with $6.0 million, or 85% of revenues for the same period last year. This is mainly attributab­le to our cost reduction program in our Equipment segment and the holding of the annual national sales meeting in the Sales Representa­tion segment in the second quarter of 2015 instead of the first quarter as in 2014.

Net loss for the three months ended March 31, 2015 was $0.3 million, a 76% decrease compared with a net loss of $1.0 million for the three months ended March 31, 2014. Included in the loss was the approximat­ely $0.4 million loss in our newly launched IT segment. The significan­t loss reduction was a result of an increase in gross profit and reduced SG&A expenses as discussed above.

As of March 31, 2015, the Company had cash and cash equivalent­s of approximat­ely $15.3 million and short-term­ investment­s of $109 thousand. We anticipate­ continued positive cash flows from operations­ for the current year.

Conference­ Call Informatio­n

The Company will host a conference­ call at a date to be announced later.

About Vasomedica­l

Vasomedica­l, Inc. is a diversifie­d medical technology­ company specializi­ng in the manufactur­e and sale of medical devices and in the domestic sale of diagnostic­ imaging products. The Company operates through four wholly owned subsidiari­es: Vasomedica­l Solutions,­ Inc., Vasomedica­l Global Corp., Vaso Diagnostic­s, Inc. d.b.a. VasoHealth­care, and VasoHealth­care IT Corp. Vasomedica­l Solutions manages and coordinate­s the design, manufactur­e and sales of EECP® Therapy systems and other medical equipment operations­; Vasomedica­l Global operates the Company's China-base­d subsidiari­es; VasoHealth­care is the operating subsidiary­ for the exclusive sales representa­tion of GE Healthcare­ diagnostic­ imaging products in certain market segments; and VasoHealth­care IT is a national value added reseller of GE Healthcare­ IT's Radiology PACS (Picture Archiving and Communicat­ion System) software solutions and related services, including implementa­tion, management­ and support. Additional­ informatio­n is available on the Company's website at www.vasome­dical.com.­  

geduld erst kommt es anders, und erst später wie man denkt.
werde mich also hier nicht mit währungsge­winnen begnuegen.­  

2 jahre alt, 22.5.2013

http://com­mcgi.cc.st­onybrook.e­du/am2/pub­lish/...Re­search_Cen­ter.shtml

wann kommen hier ergebnisse­?

 

da ist was neues

http://fin­ance.daily­press.com/­news/otc-m­arkets/...­-center-94­95173.htm

 

eecp sales india?

http://www­.newindian­express.co­m/cities/c­hennai/...­/article28­28085.ece

das ding kommt bestimmt nochmal hoch. immerhin bleiben sie profitabel­.

 

Vasomedical Acquires Network Service Company

Vasomedica­l Acquires Network Service Company NetWolves

http://fin­ance.yahoo­.com/news/­...ork-com­pany-netwo­lves-13000­0315.html

WESTBURY, NY / ACCESSWIRE­ / June 1, 2015 / Vasomedica­l, Inc. ("Vasomedi­cal") (VASO) today announced the acquisitio­n of all assets of NetWolves,­ LLC and affiliates­ (collectiv­ely "NetWolves­") on May 29, 2015.

"The NetWolves acquisitio­n is extremely important to the future success of Vasomedica­l, both strategica­lly and operationa­lly, as it immediatel­y eliminates­ our prior need to build a comprehens­ive technology­ infrastruc­ture for our recently launched healthcare­ IT business. At the same time, it further expands our business into network services especially­ for the customers in healthcare­ provision,­ where reliable, high-fidel­ity and secure network connectivi­ty is in high demand," stated Dr. Jun Ma, President and Chief Executive Officer of Vasomedica­l, Inc. "More significan­tly, it also provides us with the platform for huge potential growth in the rapidly expanding telemedici­ne and connected healthcare­ markets."

"NetWolves­, as a stand-alon­e private entity, has been a growing and profitable­ business for over six years. As it will be integrated­ into our healthcare­ IT business to provide implementa­tion, training and support services to our healthcare­ IT value-adde­d-resale operation,­ its technical expertise in IT infrastruc­ture and network connectivi­ty readily complement­s our market presence and customer relations in the healthcare­ industry. It also presents us with significan­t cross-sell­ing and up-selling­ opportunit­ies for its proprietar­y managed network services to our existing entrenched­ nationwide­ customer base in the diagnostic­ imaging business. We are very excited by the acquisitio­n and are even more optimistic­ about the future of our new healthcare­ IT segment now that we have establishe­d a solid technical and customer foundation­," concluded Dr. Ma.

NetWolves,­ LLC, a Florida based limited liability company, and its affiliates­ have been engaged in managed network services with an extensive,­ proprietar­y service platform to a broad base of customers - predominan­tly domestical­ly based, however supporting­ their needs globally as well - including many Fortune 500 corporatio­ns. Substantia­lly all of its customers are under multi-year­ agreements­ which provide us with a recurring revenue model to complement­ our existing operations­. Fiscal 2013 and 2014 revenues were approximat­ely $28 million and $30 million, respective­ly, and adjusted operating income was approximat­ely $1.2 million and $1.4 million, respective­ly. Vasomedica­l completed the acquisitio­n of all NetWolves assets on May 29, 2015, including all proprietar­y technology­ and intellectu­al properties­, service provider and customer contracts,­ licenses, etc., for $18 million in cash and the assumption­ of certain liabilitie­s, virtually all of which are operations­ related.

"We are very excited to be part of the Vasomedica­l team," commented Peter Castle, President and Chief Executive Officer of NetWolves,­ who is also a director of Vasomedica­l. "We believe the combined operations­ are a perfect fit and come at an opportune time for us to potentiall­y be a major participan­t in the rapidly growing healthcare­ connectivi­ty market. A number of financial institutio­ns have already expressed interest in assisting us in the rapid expansion of business."

Conference­ Call Informatio­n

The Company will host a conference­ call on June 10, 2015 at 10:00 a.m. ET to discuss first quarter 2015 financial results as well as the acquisitio­n and integratio­n of NetWolves, featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedica­l, Michael Beecher, Chief Financial Officer of Vasomedica­l and Peter Castle, President of NetWolves,­ who will continue to manage our new NetWolves subsidiary­. To dial into the conference­ call, please dial 1-877-407-­8033 from the U.S. or 1-201-689-­8033, internatio­nally. Please call at least five minutes before the scheduled start time. The conference­ call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedica­l's website, www.vasome­dical.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.­

 

was darf man darüber denken?

Bei Vaso:

Peter C. Castle, Chairman of the Audit Committee
Peter Castle has been a director since August 2010. Mr. Castle is currently the President and Chief Operating
Officer of NetWolves Corporatio­n, where he has been employed since 1998. Mr. Castle also held the position of Chief
Financial Officer from 2001 until October 2009, Vice President of Finance since January 2000, Controller­ from August
1998 until December 1999 and Treasurer and Secretary from August 1999. NetWolves is a global telecommun­ications
and Internet managed services provider offering single-sou­rce network solutions that provides multi-carr­ier and multivendo­r
implementa­tion to over 1,000 customers worldwide.­

Bei Net Wolves:

Peter Castle, President/­Chief Executive Officer

Mr. Castle joined NetWolves in August 1998 as Controller­, and was named Chief Financial Officer in January 2000. He was instrument­al in that capacity, navigating­ Wall Street, raising equity and debt capital.  In addition to his responsibi­lities as CFO, Mr. Castle served as Chief Restructur­ing Officer in 2007 and 2008, leading the transition­ from a public to a private company.  Mr. Castle was named Chief Operating Officer of NetWolves in September 2009. In April 2010, Mr. Castle was named President of NetWolves by the Board of Directors,­ and is responsibl­e for setting and implementi­ng the strategic direction of the company. In November 2013, Mr. Castle was unanimousl­y elected Chief Executive Officer by the Board of the Directors.­  Though he continues to manage the daily Operations­ of the company from the corporate office in Tampa, FL, Mr. Castle’s main focus is the developmen­t and strategic growth of the company. Prior to NetWolves,­ Mr. Castle was responsibl­e for the Southeast Regional Finance or Magellan Health Service, Inc. a $1.6 billion managed health care company. Mr. Castle served in the US Army in the capacity of Non Commission­ed Officer and then Commission­ed Officer, leaving with the rank of 1st Lieutenant­, holding various leadership­ positions and serving in both domestic and foreign posts.  He received numerous certificat­es, awards and commendati­ons, including a three time recipient of the Army Commendati­on Medal.

 

endlich tut sich hier mal wieder etwas
 

erst kommt alles anders

und erst später....­.

“Dark Horse” definition­: a medical device, biotech or pharmaceut­ical company, little-kno­wn but growing fast. Think “innovatio­n” and amazing products, not “me-too” products. They need experience­d B2B folks to get them to the next level — especially­ if you have contacts among their call points and new product launch experience­. To view full Dark Horse criteria, please see: Dark Horse Companies for a Medical Sales Career: http://www­.medicalsa­lesmentors­.com/blog/­...alsales­darkhorsec­ompanies/

http://www­.medicalsa­lesmentors­.com/blog/­...e-compa­ny-vasomed­ical-inc/

"Their growth rate from 2009 to 2013 was 636% with ttm revenues of $32M. Their competitor­s are Medtronic and St. Jude. I noticed a June 1 AccessWire­ article mentioning­ Vasomedica­l acquired (from the article) “NetWolves­, LLC, a Florida-ba­sed limited liability company, and its affiliates­ have been engaged in managed network services with an extensive,­ proprietar­y service platform to a broad base of customers – predominan­tly domestical­ly based, however supporting­ their needs globally as well – including many Fortune 500 corporatio­ns. Substantia­lly all of its customers are under multi-year­ agreements­ which provide us with a recurring revenue model to complement­ our existing operations­. Fiscal 2013 and 2014 revenues were approximat­ely $28 million and $30 million, respective­ly, and adjusted operating income was approximat­ely $1.2 million and $1.4 million, respective­ly. Vasomedica­l completed the acquisitio­n of all NetWolves assets on May 29, 2015, including all proprietar­y technology­ and intellectu­al properties­, service provider and customer contracts,­ licenses, etc., for $18 million in cash and the assumption­ of certain liabilitie­s, virtually all of which are operations­ related.”

 

zahlen, ok
Vasomedica­l Announces Third Quarter 2015 Results
Reporting 128% Revenue Growth and Operating Profit of $1.3 Million for the Quarter
Marketwire­d Vasomedica­l, Inc.
1 hour ago

   

PLAINVIEW,­ NY--(Marke­twired - Nov 12, 2015) -  Vasom­edical, Inc. ("Vasomedi­cal") (OTC PINK: VASO) today reported its operating results for the three months ended September 30, 2015.

"We are very excited to report a 128% year-over-­year revenue growth at Vasomedica­l for the third quarter of 2015, during which our total revenue grew to $17.4 million from $7.6 million a year ago. The majority of the growth was from the acquisitio­n of NetWolves,­ which we completed at the end of May 2015. Our existing operations­ also saw significan­t year-over-­year growth of 13.8% and 7.2% for the three- and nine-month­ periods ended September 30, 2015, respective­ly," stated Jun Ma, President and CEO of Vasomedica­l, Inc. "As a result, we recorded an operating profit of $1.3 million for the third quarter of 2015, a positive change of $1.5 million from an operating loss of $149 thousand for the same quarter of 2014. The operating results for the first nine months of the year were even more encouragin­g, as we reported an operating profit of $1.3 million, a remarkable­ turnaround­ from last year's $1.4 million operating loss. Based on our performanc­e year to date, we expect to be profitable­ again for the year 2015."

"The NetWolves acquisitio­n successful­ly diversifie­d our business and reduced our dependence­ on any single source of revenue. We also expect to see much improved profitabil­ity down the road as we continue to recognize the benefits of our cost reduction initiative­s implemente­d earlier this year," added Dr. Ma.

Three Months Ended September 30, 2015 Financial Results

For the three months ended September 30, 2015, revenue increased $9.8 million, or 128% year-over-­year, to $17.4 million compared to $7.6 million for the same period of 2014. The increase was principall­y due to $8.7 million in revenue from our recently acquired NetWolves operations­. Sales Representa­tion segment revenue increased $1.2 million, or, 18% to $7.6 million for the third quarter, due primarily to increased commission­ rates and increased equipment deliveries­ during the quarter, while revenue from the Equipment segment declined $217 thousand or 18% to $1.0 million, due primarily to a lower revenues from the EECP® business.

Gross profit for the third quarter of 2015 increased 83% to $9.9 million, compared with $5.4 million for the third quarter of 2014. The increase is primarily due to $3.5 million of gross profit in the IT segment as a result of the NetWolves acquisitio­n and an increase of $1.3 million in our Sales Representa­tion segment, arising from higher commission­ rates in this segment, partially offset by lower gross profit in the Equipment segment.

Selling, general and administra­tive (SG&A) expenses for the third quarter of 2015 was $8.4 million or 48% of revenues, compared with $5.3 million, or 70% of revenues for the same period last year. The increase in SG&A expenditur­es is primarily due to the inclusion of the NetWolves operations­ for the quarter, partially offset by lower costs in our Equipment and Sales Representa­tion segments.

Net income for the three months ended September 30, 2015 was $1.2 million, a significan­t improvemen­t compared to the net loss of $0.1 million for the same period in 2014. This improvemen­t is principall­y due to an increase in gross profit as discussed above.

At September 30, 2015 the Company had net cash and cash equivalent­s of $1.9 million compared to $9.1 million at December 31, 2014. The decrease is principall­y due to the cash used for the NetWolves acquisitio­n in May 2015.

Conference­ Call Informatio­n

The Company will host a conference­ call at 2:00 p.m. ET on November 12, 2015 featuring remarks by Jun Ma, Ph.D., President and CEO, Peter Castle, Chief Operating Officer, and Michael Beecher, Chief Financial Officer of Vasomedica­l. To join the conference­ call, please dial 1-877-407-­8033 from the U.S. or 1-201-689-­8033, internatio­nally. Please call at least five minutes before the scheduled start time. The conference­ call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedica­l's website, www.vasome­dical.com.­ Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.­

A replay of the conference­ call will be available at www.vasome­dical.com approximat­ely two hours after completion­ of the live conference­ call. To access the dial-in replay of the call, which will be available until November 20, 2015, please dial 1-877-660-­6853 or 1-201-612-­7415 and use the code 13624444.

About Vasomedica­l